Profund Advisors LLC Acquires 14,820 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Profund Advisors LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 84.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,416 shares of the company’s stock after purchasing an additional 14,820 shares during the period. Profund Advisors LLC’s holdings in CRISPR Therapeutics were worth $1,751,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. lifted its holdings in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares during the last quarter. Global Trust Asset Management LLC lifted its holdings in CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC lifted its holdings in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the last quarter. NBC Securities Inc. raised its holdings in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after acquiring an additional 438 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC raised its holdings in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on CRSP shares. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Rodman & Renshaw started coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Finally, Piper Sandler reissued an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Monday, June 17th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $75.63.

CRISPR Therapeutics Stock Down 2.6 %

Shares of CRSP stock opened at $48.18 on Monday. The stock’s fifty day simple moving average is $50.45 and its 200 day simple moving average is $56.83. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm has a market capitalization of $4.09 billion, a P/E ratio of -17.71 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the previous year, the business earned ($0.98) EPS. The company’s revenue was down 99.3% on a year-over-year basis. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.